The global wound care market recently reached revenues of more than $20 billion (http://dtn.fm/W1wjB) at the end of 2016, based on sales at the manufacturer’s level. Specifically, the burn care market is expected to grow at a CAGR of 6.8% from $1.68 billion in 2016 to more than $2.33 billion by the end of 2021 (http://dtn.fm/I6abR). The growth in these markets has been largely attributed to factors such as the rising number of burn accidents, an aging population, and the rise in cardiovascular diseases, diabetes, obesity, and other diseases that can cause skin-related problems.
Currently, wound care ranges from anti-infectives, ulcer wound management, moist dressings, and negative pressure wound therapy to wound closure and even conventional skin grafts. These treatments can be extremely painful, slow-to-heal, and are more likely to face complications along the way. Today, more is being done to help patients suffering from skin problems, some of which include a rise in health care expenditure, more government initiatives, an increase in the number of emergency centers and burn units, and a growing understanding of the various treatment options.
In addition, more innovative forms of treatment are slowly being introduced. RenovaCare, Inc. (OTCQB: RCAR), a development stage biotechnology company focused on acquiring, researching, developing, and commercializing first-of-their-kind self-donated stem cell therapies for the regeneration of human organs, is in the process of developing a product that targets issues relating to the human body’s largest organ, the skin.
The company’s CellMist™ system uses a patient’s own stem cells and is applied onto wounds and burns using its SkinGun™. The technology is able to regrow the skin across wounds by spreading numerous regenerative islands over the affected area, rather than the wound healing from the outside in. Although still part of an experimental setting, the system has been tested on patients such as Matt Uram, a victim of a fire-related accident during a July fourth celebration, who, within three days witnessed incredible results, with burns almost completely healed and no risk of infection or scarring (http://dtn.fm/uXAR5).
RenovaCare believes the SkinGun™ could replace today’s standards of care, decreasing the need for patients to go through the process of having complicated skin grafts, mesh skin grafts, and other forms of painful treatment.
The company is aiming to get the SkinGun™ FDA-approved in the near future, and research is already underway at RenovaCare to enable the treatment of third degree burns, which are more complex in nature and often come with damage to the muscles and tissue below the skin.
For more information, visit www.RenovaCareInc.com
